Effects of dihydrotanshinone I on proliferation and invasiveness of paclitaxel-resistant anaplastic thyroid cancer cells by Allegri, L. et al.
 International Journal of 
Molecular Sciences
Article
Effects of Dihydrotanshinone I on Proliferation and
Invasiveness of Paclitaxel-Resistant Anaplastic Thyroid
Cancer Cells
Lorenzo Allegri 1, Francesca Capriglione 2, Valentina Maggisano 2, Giuseppe Damante 1,3,* and Federica Baldan 3


Citation: Allegri, L.; Capriglione, F.;
Maggisano, V.; Damante, G.; Baldan,
F. Effects of Dihydrotanshinone I on
Proliferation and Invasiveness of
Paclitaxel-Resistant Anaplastic
Thyroid Cancer Cells. Int. J. Mol. Sci.
2021, 22, 8083. https://doi.org/
10.3390/ijms22158083
Academic Editor: Mirela Sedic
Received: 8 July 2021
Accepted: 27 July 2021
Published: 28 July 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Institute of Medical Genetics, Academic Hospital of Udine, Azienda Sanitaria Universitaria Integrata di
Udine, 33100 Udine, Italy; allegri.lorenzo@spes.uniud.it
2 Department of Health Sciences, University of Catanzaro ‘Magna Graecia’, 88100 Catanzaro, Italy;
francesca.capriglione@studenti.unicz.it (F.C.); vmaggisano@unicz.it (V.M.)
3 Department of Medicine, University of Udine, Via Chiusaforte, 33100 Udine, Italy; federica.baldan@uniud.it
* Correspondence: giuseppe.damante@uniud.it
Abstract: ATC is a very rare, but extremely aggressive form of thyroid malignancy, responsible for the
highest mortality rate registered for thyroid cancer. In patients without known genetic aberrations,
the current treatment is still represented by palliative surgery and systemic mono- or combined
chemotherapy, which is often not fully effective for the appearance of drug resistance. Compre-
hension of the mechanisms involved in the development of the resistance is therefore an urgent
issue to suggest novel therapeutic approaches for this very aggressive malignancy. In this study, we
created a model of anaplastic thyroid cancer (ATC) cells resistant to paclitaxel and investigated the
characteristics of these cells by analyzing the profile of gene expression and comparing it with that of
paclitaxel-sensitive original ATC cell lines. In addition, we evaluated the effects of Dihydrotanshi-
none I (DHT) on the viability and invasiveness of paclitaxel-resistant cells. ATC paclitaxel-resistant
cells highlighted an overexpression of ABCB1 and a hyper-activation of the NF-κB compared to
sensitive cells. DHT treatment resulted in a reduction of viability and clonogenic ability of resistant
cells. Moreover, DHT induces a decrement of NF-κB activity in SW1736-PTX and 8505C-PTX cells. In
conclusion, to the best of our knowledge, the results of the present study are the first to demonstrate
the antitumor effects of DHT on ATC cells resistant to Paclitaxel in vitro.
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1. Introduction
Thyroid cancer (TC) is the most common endocrine carcinoma, accounting for 1–2%
of cancer cases worldwide [1]. Most thyroid carcinomas derive from follicular cells and
are classified according to their differentiation levels in differentiated thyroid cancer, in-
cluding papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) and in poorly
differentiated thyroid cancer or anaplastic thyroid cancer (ATC) [1]. While PTC and FTC,
which account for more than 95% of tumors, are mostly responsive to the current treatment
based on surgery and following radioiodine therapy, resulting in an overall survival rate of
over 90% within 10 years, ATCs are a very rare, but extremely aggressive form of thyroid
malignancy. They are mostly diagnosed as stage IV disease [1], often are not resectable,
and do not respond to radioactive iodine ablation for their undifferentiated phenotype due
to the loss of thyroid-specific gene expression [2]. For these reasons and considering its
extremely fast-growing and aggressive nature, ATC, although representing less than 2% of
all thyroid malignancies, is responsible for 20–50% of thyroid cancer mortality [3].
The current management of ATC has strongly been conditioned by the advent of the
molecular testing of thyroid tumors which permits to target the known genetic mutations [4]
with the new molecular drugs, mainly inhibitors of tyrosine kinases [5,6]. However, for
the tumors resistant to these new drugs and those without known detectable genetic
Int. J. Mol. Sci. 2021, 22, 8083. https://doi.org/10.3390/ijms22158083 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2021, 22, 8083 2 of 17
aberrations, the current treatment is still represented by palliative surgery and systemic
chemotherapy, the latter consisting in taxane monotherapy or combined with carboplatin
or anthracyclines [7]. Unfortunately, even the combined drug treatments easily induce drug
resistance and, in the absence of further reliable therapy, patients with ATCs are destined
to shortly die due to unlimited local growth and distal metastases dissemination [6,7].
Comprehension of the mechanisms involved in the development of drug resistance has
become therefore urgent for improving the prognosis of this very aggressive malignancy.
In this context, a pivotal role in promoting cancer resistance to chemotherapy is played
by Nuclear factor-kappa B (NF-κB), a transcription factor that regulates the expression of
various genes that are crucial for cancer development and progression [8,9]. The role of
NF-κB in thyroid cancer has extensively been investigated, especially in ATC suggesting
a major involvement in thyroid tumor genesis and progression [10,11]. Interestingly,
inhibition of NF-κB by ectopic expression of a super-repressor form of IκBα in an ATC-
derived cell line leads to an increased susceptibility to chemotherapeutic drug-induced
apoptosis, and the block of the oncogenic activity [11]. Bringing all these data together
and considering the influence of NF-κB on the expression of the multidrug resistance gene
(MDR1), this transcription factor may be also considered as involved in the development
of drug resistance in ATCs.
The overexpression of elements of MDR is a well-established cause of therapeutic
failure in human cancer. In MDR cells, a key role is played by ATP binding cassette
(ABC) transporters, integral membrane pumps responsible for the efflux of drugs from
tumor cells [12]. ATP binding cassette subfamily B member 1 (ABCB1), encoded by MDR1,
the most typical ABC transporter, expels non-polar compounds from the cytosolic side
of the membrane to the extracellular space. In the literature, it is well described that
ABCB1 overexpression produces MDR in different cancer cells inducing the decrease in the
intracellular concentration of ABCB1 substrates, such as taxanes [13,14]. Numerous in vitro
and in vivo studies have stated that the overexpression of ABCB1 is involved in mediating
resistance to PTX and docetaxel in various types of cancers [15,16]. ATCs exhibit over- and
co-expression of different ABC transporters, resulting in amplification of the resistance to a
single agent or in multidrug resistance to different compounds [17]. Moreover, inhibition
of ABCB1 restores the sensitivity to doxorubicin in a cancer stem cells-rich ATC cell-line as
demonstrated by Zheng et al. [18]. These findings suggest that ABCB1 plays a key role in
chemotherapy resistance development in ATC.
In recent years, phytochemicals have taken a leading role in the search for new drugs
capable of fighting cancer. Indeed, many plants extracted compounds have attracted
particular attention as agents provided with anticancer activity and tested in preclinical
models of several malignancies [19,20]. Among the phytochemicals tested against ATC
cancer cells [21–23], particular attention has been focused on 15,16-dihydrotanshinone I
(DHT), a tanshinone extracted from Salvia miltiorrhiza Bunge (Danshen), one of the most
frequently prescribed herbs in traditional Chinese medicine [24]. DHT has not only shown
promising anticancer effects in numerous in vitro models of many types of cancer, in-
cluding ATC [25–27], but has also been tested in animal models, confirming its ability to
inhibit tumor growth with no adverse effects on healthy tissues [28,29]. Moreover, Hu
et al. demonstrated that DHT plays an important role in circumventing colon cancer cell
resistance by down-regulating ABCB1 expression and inhibiting its ATPase activity, thereby
increasing intracellular accumulation of the transporter substrate anticancer drugs [30].
Altogether, these findings indicate that DHT is a candidate that may be tested as a novel
anticancer agent in ATC treatment.
In this study, we created a model of anaplastic thyroid cancer cells resistant to pa-
clitaxel, to investigate the characteristics of these cells by analyzing the profile of gene
expression and comparing it with that of paclitaxel-sensitive original ATC cell lines. In
addition, we evaluated the effects of Dihydrotanshinone I on the viability and invasiveness
of paclitaxel-resistant cells.
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2. Results
2.1. Generation of Paclitaxel-Resistant Anaplastic Thyroid Cancer Cells and Paclitaxel Effects on
Cell Viability
We used ATC cell lines SW1736 and 8505C to obtain the two parental cell lines resistant
to paclitaxel (SW1736-PTX and 8505C-PTX) by the administration of the drug at increasing
doses. In the first set of experiments, we evaluated the response to PTX in both wild-type
(wt) and resistant ATC cell lines. To test the effects on cell viability of several doses of
PTX, we performed an MTT assay after treating ATC cells for 72 h. As shown in Figure 1A,
PTX treatment significantly reduced the viability in both wt ATC cell lines when used at
a concentration equal or greater than 0.5 nM. The EC50 was 3.2 ± 0.57 nM in SW1736
and 4.3 ± 0.21 nM in 8505C. At variance, resistant ATC cell SW1736-PTX and 8505C-PTX
were not sensitive to these low doses, and for this reason, we tested their viability using
higher PTX concentrations. After 72 h PTX treatment, the viability in both PTX-resistant
cell lines was significantly reduced after administration of PTX concentration higher than
1.75 µM and EC50 shifted to 4.2 ± 0.2 µM and 4.9 ± 0.3 µM in SW1736-PTX and 8505C-PTX
respectively (Figure 1B).
Figure 1. Effects of paclitaxel in ATC cell line cell viability. (A) SW1736 and 8505C parental and
paclitaxel-resistant (SW1736-PTX and 8505C-PTX) cells were treated with paclitaxel at different doses
(rising from 0.25 nM to 10 nM) or vehicle (DMSO) for 72 h and cell viability was assessed by MTT
assay. (B) SW1736 and 8505C paclitaxel-resistant cells were treated with paclitaxel at different doses
(rising from 1 µM to 10 µM) or vehicle (DMSO) for 72 h and cell viability was assessed by MTT assay.
Each point represents the mean of six measurements. n = 6. p values are enlisted in Supplementary
Tables S1 and S2.
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2.2. ATC and ATC-PTX Cell Lines Gene Expression Analysis
To identify the molecular mechanism behind the acquisition of resistance to PTX, we
performed a high-throughput RNA sequencing analysis on SW1736 and 8505C cells and
on SW1736-PTX and 8505C-PTX cells. To assess the gene expression changes induced
by the acquisition of the resistance, a comparison between wild-type and resistant cells
was performed. Heat maps representing each analyzed condition are shown in Figure 2A.
Expression of 13,919 and 13,386 genes was detected in SW1736 and 8505C cells, respectively.
After filtering low quantity reads, approximately 3800 genes were differentially expressed
between wild type and resistant SW1736 cells, while in 8505C cells, the differentially
expressed genes were ∼3200 (at a log2 fold change > 1.5). Among them, 2308 genes
resulted significantly up-regulated and 1531 were down-regulated in SW1736-PTX cells
compared to wt SW1736. In 8505C cells, 2279 genes were up-regulated and 909 were down-
regulated in response to resistance acquisition. The top 10 up- and down-regulated genes
for each cell line are enlisted in Tables 1 and 2. The principal component analysis (PCA)
revealed a clear separation of SW1736 and 8505C wild-type cells and resistant cells. PCA
resulted in a separation of wild type and PTX resistant samples along the first principal
component (PC1) with 59.7% explained variance, and 23.6% explained variance along the
second principal component (PC2) (Figure 2B). Comparison of the enriched genes in both
cell lines showed that 1516 genes were commonly altered in the two ATC-PTX cell lines.
Figure 2. Paclitaxel-resistance effects on gene expression. (A) Heat maps showing the hierarchical
clustering of mRNA in SW1736 and 8505C cells and in SW1736-PTX and 8505C-PTX cell lines. Results
are showed as Fold Change (Log2). (B) Principal Component Analysis (PCA) results. Each point
represents an RNA-Seq sample. Samples with similar gene expression profiles are clustered together.
(C) Venn diagrams represented the comparison of up-regulated, down-regulated between SW1736-
PTX and 8505C-PTX cell lines after RNA-seq data analysis. Within the intersection of the circles are
indicated the shared modified genes between the two cell lines.
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Table 1. Top 10 up- and down-regulated genes in SW1736-PTX cells.
Top-10 Up-Regulated Genes Top-10 Down-Regulated Genes
Gene ID SW1736 FPKM SW1736-PTX FPKM Gene ID SW1736 FPKM SW1736-PTX FPKM
SLC25A6 0 1068.014282 CRIP1 121.2277 0
CD99 0 438.171265 INHBA 120.7393 0
SFRP1 0 353.209839 G0S2 110.1006 0
ABCB1 0 302.292755 TMEM200A 80.16118 0
ASS1 0 272.908447 MT1L 70.32181 0
MMP1 0 253.921478 CDCA7L 64.91097 0
KISS1 0 227.140152 PEG10 59.8796 0
CD24 0 161.055496 CDH13 56.48613 0
LAMA5 0 128.902344 GNG11 48.80974 0
EPB41L3 0 111.837128 LIF 47.06105 0
Table 2. Top 10 up- and down-regulated genes in 8505C-PTX cells.
Top-10 Up-Regulated Genes Top-10 Down-Regulated Genes
Gene ID 8505C FPKM 8505C-PTX FPKM Gene ID 8505C FPKM 8505C-PTX FPKM
SLC25A6 0 906.9684 PSMD5 4.736901 0
ABCB1 0 497.1158 STEAP1 4.928442 0
CD99 0 344.5431 VEPH1 5.764932 0
NUPR1 0 117.2764 NLGN4X 6.481269 0
ASMTL 0 44.84652 IL1RL1 7.034636 0
ERV3-1 0 42.39337 RPL36A-HNRNPH2 7.240747 0
ALPPL2 0 36.63164 CDCP1 8.863821 0
WFDC21P 0 33.00259 ZNF702P 8.940498 0
ZNF117 0 31.36288 UCHL1 24.07678 0
PIEZO2 0 28.97086 CBWD5 67.27538 0
In Figure 2C, Venn diagrams show that 1131 genes were commonly up-regulated and
385 were down-regulated. The common differentially expressed genes were then subjected
to ontology-based Pathway Analysis in order to outline which pathways were mostly
affected by Paclitaxel resistance acquisition. Various signaling cascades turned out to be
modified in ATC-PTX cells: inflammation mediated by chemokine and cytokine signaling
and integrin signaling proved out to be among the most deregulated pathways, since
numerous genes involved in these pathways were both up- and down-regulated (Figure 3).
Figure 3. Cont.
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Figure 3. Top 20 deregulated pathways. (A) Top 20 common and up-regulated pathways in SW1736-
PTX and 8505C-PTX cells. (B) Top 20 common down-regulated pathways in SW1736-PTX and
8505C-PTX. Pathway analysis was performed using the Panther classification system.
In order to assess the transcription factors most involved in the gene expression
deregulation due to the acquisition of paclitaxel resistance, the database TRRUST [31] was
queried. Tables 3 and 4 enlist the top 10 transcription factors involved in the common
genes up-regulation and down-regulation, respectively. Among them, SP1, NF-kB and
TP53 appear to be strongly involved in both inducing and repressing gene expression of
commonly deregulated genes in ATC-PTX cells.
Table 3. Regulators of common up-regulated genes.
Key TF Description # of Overlapped Genes
SP1 Sp1 transcription factor 10
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 8
SPI1 spleen focus forming virus (SFFV) proviral integration oncogene spi1 5
WT1 Wilms tumor 1 4
STAT1 signal transducer and activator of transcription 1, 91 kDa 4
JUN jun proto-oncogene 4
TP53 tumor protein p53 4
RFXANK regulatory factor X-associated ankyrin-containing protein 3
RFXAP regulatory factor X-associated protein 3
RFX5 regulatory factor X, 5 3
TF: transcriptor factor.
Table 4. Regulators of common down-regulated genes.
Key TF Description # of Overlapped Genes
E2F1 E2F transcription factor 1 12
SP1 Sp1 transcription factor 10
TP53 tumor protein p53 7
MYCN v-myc myelocytomatosis viral related oncogene, 5
MYC v-myc myelocytomatosis viral oncogene homolog 5
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 5
SRF serum response factor 4
BRCA1 breast cancer 1, early onset 4
TFDP1 transcription factor Dp-1 3
RB1 retinoblastoma 1 3
TF: transcriptor factor.
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2.3. Activation of STAT 3 and ERK in Wild Type and Paclitaxel-Resistant ATC Cells
To investigate the involvement of signal transduction pathways activated by the most
frequent genetic alterations detected in ATC cells in the cells with acquired resistance to
PXT, we performed an immunoblot analysis to measure the expression levels of phospho-
rylated STAT3 and ERK, markers of activation of JAK/STAT and ERK/MAPK pathways
respectively. As shown in Figure 4, we observed a slight decrease in phospho-STAT 3 pro-
tein expression levels in SW1736 and 8505C paclitaxel-resistant cells, compared to the
parental cells. In the same experimental conditions, no variation of phospho-ERK levels
was observed.
Figure 4. Expression levels of STAT 3 and ERK in wild type and Paclitaxel-resistant ATC cells.
(A) Immunoblot analysis of phosphorylated ERK (p-ERK) and phosphorylated STAT 3 (p STAT3),
and total form of the enzymes (ERK, STAT3), was performed by Western blotting in parental and
Paclitaxel-resistant (-PTX) SW1736 and 8505C cells. β-actin was used as loading control. n = 3.
(B) Densitometric analysis of p-ERK/ERK. n = 2. Panel (C) Densitometric analysis of p-STAT3/STAT3.
n = 3. Values are expressed as fold over control. Statistical analysis was performed using the Tukey–
Kramer multiple comparisons test. * p < 0.05 vs. control.
2.4. Effects of DHT on Cell Viability and Cell Colony Formation Ability in ATC-PTX Cell Lines
In order to assess the effects of DHT on the viability of PTX-resistant ATC cells, we
carried out an MTT assay on SW1736-PTX and 8505C-PTX after treatment with increasing
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DHT doses for 24, 48 or 72 h. In SW1736-PCTX the two highest doses (2 and 3 µM) reduced
cell viability after 24, 48, and 72 h treatment (Figure 5A); conversely, in 8505C cells, all doses
tested were able to significantly reduce the cell viability at each time point (Figure 5B).
Based on these data, the 2.5 µM dose and 72 h treatment were considered as the common
EC50 of the two cell lines and used in the further experiments. To assess the effects of
DHT on other characteristics of aggressiveness in the two ATC-PTX cell lines, we assessed
its influence on the ability of cells to form colonies in an anchorage-independent way, by
performing a soft agar colony formation assay. As shown in Figure 5C,D, there was a
significant reduction in the number of colonies when cells were treated with 2.5 µM DHT. In
8505C cells, DHT reduced the number of colonies by approximately 10-fold, and its effects
were stronger on SW1736 cells, in which it completely abrogated colony formation ability.
Figure 5. DHT effects in paclitaxel-resistant ATC cells. Panel (A,B): SW1736-PTX (A) and 8505C-PTX
(B) cells were treated with DHT at different doses (rising from 0.5 µM to 3 µM) or vehicle (DMSO)
for 24, 48 and 72 h and cell viability was assessed by MTT assay. Panel (C,D): SW1736-PTX and
8505C-PTX cells were treated with DHT 2.5 µM and their ability of forming colonies was evaluated
by soft agar assay. Representative bar chart of the number of colonies after 21 days in SW1736-PTX
(C) and 8505-PTX (D) cells. n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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2.5. Effects of DHT on Gene and Protein Expression in ATC-PTX Cells
In order to study the molecular mechanisms underlying the effects of DHT in resistant
cells, we focused on commonly up-regulated genes. We analyzed the variation in the
gene expression levels following the treatment with DHT of commonly up-regulated genes
present in the top 10: SLC25A6, ABCB1 and CD99. Among selected commonly up-regulated
genes, in SW1736-PTX, DHT induced a significant decrease only in ABCB1 expression after
treatment at 2.5 µM concentration for 72 h (Figure 6A). The same effect on ABCB1 was also
observed in 8505C-PTX cells, in which treatment with DHT also determined an increase in
CD99 expression (Figure 6B).
Figure 6. Effects of DHT on gene and protein expression in ATC-PTX cells. SW1736-PTX and
8505C-PTX cells were treated with DHT 2.5 µM or vehicle. Panel (A,B): Relative expression levels
of three commonly deregulated mRNA in SW1739-PTX (A) and 8505C-PTX (B) following 2.5 µM
DHT treatment for 72 h. Data are normalized against β-actin levels. (C) ABCB1 protein levels in
SW1736-PTX and 8505C-PTX cells treated with DMSO or 2.5 µM DHT for 72 h. (D) Densitometric
analysis of ABCB1 protein levels in ATC-PTX cells treated with 2.5 µM DHT or DMSO. Data are
normalized against β-actin levels. n = 3. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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Since DHT was shown to revert ABCB1 overexpression in both resistant cell lines,
we evaluated its protein levels after treatment with DHT. First, we confirmed its over-
expression also at the protein level in both resistant cell lines. Then we assessed the
effects of treatment with DHT 2.5 µM for 72 h: immunoblot analysis showed a significant
reduction in ABCB1 expression in both SW1736-PTX and 8505C-PTX cells (Figure 6C,D).
2.6. Effects of DHT on NF-kB Levels and Activation in ATC-PTX Cell Lines
To better understand the mechanism underlying ABCB1 dysregulation in ATC-PTX
cells, in light of the results obtained after high-throughput RNA sequencing analysis, we
focused our attention on the transcription factor NF-κB. NF-κB protein expression levels
were assessed in ATC cells, and ATC-PTX cells treated with vehicle or 2.5 µM DHT for 72 h.
As shown in Figure 7A,B, resistant cells present a strong and significant increase in NF-κB
protein expression, and this increment is removed following DHT treatment. However,
the total amount of NF-κB within the cell is not a sufficient indicator of its activation
status. When its activation pathway is turned on, NF-κB migrates from the cytoplasm
into the nucleus, where it can activate the transcription of its target genes. Therefore, in
order to obtain a more meaningful result about the role of this transcription factor, we also
evaluated the relationship between the nuclear and cytoplasmic forms of NF-κB. Figure 7C
shows that this ratio was increased in resistant SW1736 cells compared to the non-resistant
parental cell line, indicating a hyper-activation, while DHT treatment again was able to
bring NF-κB activation back to normal levels. In 8505C cells, no significant changes in the
nucleus–cytoplasm ratio are noted. Taken together, these results indicate that in resistant
cells NF-κB is up-regulated and that DHT is able to restore its expression and activation to
the levels observed in non-resistant cells.
Figure 7. Effects of DHT on NF-κB in ATC and ATC-PTX cells. SW1736 and 8505C cells, both parental
and paclitaxel-resistant, were treated with DHT 2.5 µM or vehicle. (A) NF-κB protein levels in ATC
and ATC-PTX cells treated with DMSO or 2.5 µM DHT for 72 h. (B) Densitometric analysis of NF-κB
protein levels in ATC and ATC-PTX cells treated with 2.5 µM DHT or DMSO. Data are normalized
against β-actin levels. (C) Densitometric analysis of NF-KB nuclear/cytoplasmatic protein levels ratio
in ATC and ATC-PTX cells treated with 2.5 µM DHT or DMSO. Cytoplasmatic data are normalized
against β-actin levels and nuclear data are normalized against Lamin B1. n = 3. * p < 0.05, ** p < 0.01,
*** p < 0.001.
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3. Discussion
A combination of surgical removal of the thyroid gland and lymph nodes, with
treatment with radioactive iodine (RAI), associated with long-term thyroid hormone sup-
pression is highly efficacious for the majority of thyroid cancers [32]. Conversely, this
approach is not effective in the radioiodine refractory DTC and especially in ATC. For
these extremely aggressive malignancies, promising effects are being obtained by the use
of novel therapeutic approaches [5,6,33], but, in many cases, the resistance to the current
treatments is still a fundamental unresolved issue.
In this study, we focused our attention on the molecular mechanism involved in the
acquisition of resistance to the treatment with paclitaxel, a taxane still indicated in mono-
or multi-therapy for those tumors in which the molecular signature does not suggest the
use of personalized treatment with a tyrosine kinase inhibitor [7]. Thus, we first created a
model of ATC cells resistant to paclitaxel treatment, using two human cell lines derived
from human ATCs and examining their characteristics by the evaluation, firstly, of the
gene expression differences between paclitaxel-sensitive parental lines and those in which
resistance had developed. Data obtained from the RNA-seq analysis indicate how the
acquisition of paclitaxel resistance is associated overall with an increase in the expression of
3456 genes and a down-regulation of 2055 genes. More in detail, the genes commonly up-
regulated in the two lines turn out to be 1131, while those commonly down-regulated were
385. SW1736 and 8505C, despite being both cell lines derived from ATC, present important
differences at gene expression level, reproducing the high variability shown in the behavior
of human ATCs, but these differences are significantly reduced after the acquisition of
resistance to Paclitaxel. The similarity in the transcriptional signature between the two
resistant cell lines suggests that the mechanism of resistance acquisition may be common
and finely regulated rather than the result of random events.
Analyzing the pathways in which commonly up- or down-regulated genes are involved,
we found that the one concerning inflammation mediated by cytokine and chemokine signal-
ing turns out to be one of the most altered. SLC25A6, CD99, and ABCB1 were the single
genes most commonly up-regulated in the two resistant cell lines. SLC25A5 is strongly
over-expressed in various types of human cancer cells [34], while the role of CD99 in cancer
is more controversial, since it behaves as an oncogene in most cancers, whereas in some
types of neoplasia it behaves as a tumor suppressor gene [35]. ABCB1 is a transporter
of neutral or positively charged hydrophobic compounds and xenobiotics out of the cell,
thereby protecting them from cytotoxicity [36]. ABCC1 has been described as the most
highly expressed transporter in ATC [17], and also appears to be overexpressed follow-
ing treatment with Paclitaxel and Docetaxel in these tumors, thus largely explaining the
acquisition of chemoresistance [37,38].
Using as input the up- and down-regulated genes in the two ATC-PTX cell lines, we
also identified the transcription factors most involved in the acquisition of resistance to
Paclitaxel. Of particular interest was the presence among them of NF-κB as one of the
transcription factors most involved, the importance of the NF-κB cascade described in
different stages of thyroid cancer [10]. In addition, the JAK/STAT pathway seems to be
involved as acquired in the resistant ATC cells in which reduced levels of phosphorylated
STAT3 were detected compared to the parental cells. These findings are consistent with
the hypothesis of a protective rather than promoting the role of this pathway in the
development and progression of thyroid cancer [39], also suggesting a relationship with
the acquisition of drug resistance activation.
In previous studies, we and others have already shown that the use of compounds
extracted from plants is potentially useful in counteracting the growth of ATC cells in
preclinical experimental models [20–22,40,41]. In particular, we demonstrated that DHT, a
lipophilic abietane diterpene compound extracted from the dried root of Salvia miltiorrhiza,
has an antitumor action in ATC cell lines, and this action is in part mediated by the
regulation of the HuR-MAD2 axis known to be involved in the proliferation, survival and
aggressiveness of this tumor [42,43]. In this study, we evaluated the effects of DHT on
Int. J. Mol. Sci. 2021, 22, 8083 12 of 17
ATC cell lines resistant to Paclitaxel and found that DHT was effective in reducing cell
viability in SW1736-PTX and 8505C-PTX cells with an EC50 absolutely comparable with
that observed in non-resistant ATC cells in our previous work [27]. Lee et al. demonstrated
that DHT treatment induces a decrease in cell population in the Gl phase, an increase
in the S phase cells and apoptosis in erythroleukemia cells resistant to Adriamycin [44].
These results are consistent with those we observed in ATC cells treated with DHT [27],
suggesting a similar mechanism underlying the effects observed in ATC-PTX cells.
Furthermore, DHT treatment was able to almost completely reduce the ability to form
colonies in an anchorage-independent manner in both cell lines. By analyzing the effects of
DHT on the expression of the most relevant up-regulated genes identified after RNA-seq,
we found that while the treatment was unable to counteract the increased expression of
SLC25A6 and CD99 following the acquisition of resistance, DHT significantly reduced
ABCB1 mRNA levels in both ATC-PTX cell lines. Analysis of ABCB1 protein levels also
confirmed both its overexpression following the development of resistance and its strong
down-regulation following DHT treatment in resistant cells. The effects of DHT on ABCB1
in resistant cells that we observed are in agreement with the results of Hu et al. [30],
suggesting that part of the antitumor effects of DHT observed in resistant cells are due to
the reduction of ABCB1 expression.
In order to identify a molecular mechanism upstream of ABCB1 down-expression,
we shifted our attention to the activation state of NF-κB. A number of NF-kB inhibitors
have been demonstrated to induce anti-proliferative and anti-apoptotic effects against
thyroid cancer cells, and various anticancer compounds exert their effects by blocking
this pathway [10,45–47]. Our finding revealed that NF-κB is one of the transcription
factors most involved in the acquisition of Paclitaxel resistance in SW1736-PTX and 8505C-
PTX cells, which is consistent with the known effect of NF-κB on the increase in ABCB1
expression [9]. By analyzing total protein levels and the ratio of nuclear versus cytoplasmic
levels, we also demonstrate that NF-κB appears to be up-regulated in resistant cell lines
compared to sensitive ones, whereas DHT treatment results in a reduction of NF-κB activity
in SW1736-PTX and 8505C-PTX cells. This finding allows us to hypothesize that inhibition
of NF-κB activity may be one of the mechanisms underlying the down-regulation of ABCB1.
Considering the wide range of pathways on which DHT is active, other mechanisms of
action, such as the regulation of intracellular calcium mobilization already observed by
Park et al. [48], STAT-3 and other transduction signaling pathways, could be involved and
more in-depth studies are advisable.
In conclusion, to the best of our knowledge, the results of the present study are the first
to demonstrate the antitumor effects of DHT on ATC cells resistant to Paclitaxel in vitro.
Despite these encouraging results, this study is limited by the lack of validation of the
results by using an in vivo model. Therefore, further and more detailed studies on DHT
effects on ABCB1 and NF-κB regulation, as well as in vivo investigation of this compound
in combination with paclitaxel or other anticancer compounds, are needed in view of
testing it in clinical trials.
4. Methods
4.1. Cell Lines
SW1736 and 8505C cells, derived from human ATC, were cultured in RPMI-1640
medium (Euroclone S.p.A, Milano, Itlay) supplemented with 10% FBS (Gibco; Thermo
Fisher Scientific, Inc., Waltham, MA, USA), 2 mM L-glutamine (Euroclone S.p.A) and
50 mg/mL gentamicin (Gibco; Thermo Fisher Scientific, Inc.). Cells were cultured in a
humidified incubator (5% CO2 and 95% air at 37 ◦C) (Eppendorf AG, Hamburg, Germany).
Both cell lines were validated using short tandem repeat analysis and confirmed to be
mycoplasma-free. SW1736 and 8505C cells were treated with DMSO (vehicle; Sigma-
Aldrich; Merck KGaA, Darmstadt, Germany), DHT (purity ≥ 99%; Selleck Chemicals,
Houston, TX, USA) or Paclitaxel (Selleck Chemicals). The DHT was prepared by dissolving
2 mg of powder in 2 mL of DMSO, resulting in a 3.6 mM stocking solution.
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To obtain ATC paclitaxel-resistant cell lines (SW1736-PTX and 8505C-PTX), the two
parental cell lines were treated with increasing doses of paclitaxel arising from 1 nM to
1.5 µM for 6 months. Resistance to pacitaxel was considered to be acquired when a 1.5 µM
dose resulted in no effect in terms of cell viability. Resistant cells were cultured in RPMI-
1640 medium supplemented with 10%, 2 mM L-glutamine, 50 mg/mL gentamicin and
paclitaxel 1.5 µM.
4.2. Cell Viability
In order to test cell viability, the MTT assay was used. SW1736 and 8505C cells, parental
and PTX-resistant, were seeded in 96-well plates (4 × 103 cells/well). The following day,
cells were treated with paclitaxel (from 0.25 nM to 10 nM in parental cells and from 1 µM
to 5.5 µM in resistant cells), DHT (from 0.5 µM to 3 µM) or vehicle (DMSO) at different
concentrations. After 24, 48 or 72 h of incubation, 4 mg/mL MTT (Sigma-Aldrich; Merck
KGaA) was added to the cell medium and cells were cultured for a further 4 h in the
incubator in the dark. The supernatant was removed, 100 µL/well DMSO (Sigma-Aldrich;
Merck KGaA) was added, and the absorbance at 570 nm was measured. All experiments
were performed as six technical repeats and cell viability is expressed as the fold-change
relative to the control (DMSO-treated cells).
4.3. High-Throughput RNA Sequencing and Analysis
RNA was extracted from SW1736 and 8505C cells and from SW1736-PTX and 8505C-
PTX cells using a RNeasy Mini kit (Qiagen GmbH, Venlo, Netherlands) according to the
manufacturer’s instructions. In total, ~1 µg RNA (RNA integrity number > 7) was used
as the starting material for preparation of the library using a Universal Plus mRNA-Seq
kit (catalog number 0520-A01; Tecan Group, Ltd., Männedorf, Svizzera) according to the
manufacturer’s protocol. RNA samples were quantified, and the quality was assessed using
an Agilent 2100 Bioanalyzer RNA assay (Agilent Technologies, Inc., Santa Clara, CA, USA)
and the final libraries were checked using both a Qubit 2.0 Fluorometer (Invitrogen; Thermo
Fisher Scientific, Inc.) and Agilent Bioanalyzer DNA assay. The library final concentration
was 68.7 nM. Libraries (1.4 nM) were then prepared for sequencing using the single-end
75 bp mode on a NextSeq 500 (Illumina, Inc., San Diego, CA, USA). The Bcl2Fastq version
2.20 in the Illumina pipeline was used for processing the raw data (format conversion and
de-multiplexing); adapter sequences were masked with Cutadapt version 1.11 [49] from
raw fastq data and the ERNE [50] software was used to remove lower quality bases and
adapters. Reads were aligned to the reference hg38 genome/transcriptome using STAR
software [51]. Finally, assembly and quantitation of full-length transcripts representing
multiple spliced variants for each gene locus were performed using the Stringtie tool [52].
For further analysis, we selected effective data for those with FPKM values > 0.5 and log2
fold-change > 1.5 or <−1.5. Raw and processed data are available on the public online
repository Gene Expression Omnibus (dataset no. GSE179786).
4.4. Gene Expression Assay
A total of 500 ng total RNA from SW1736 and 8505, parental or resistant, cells was
extracted as described above, and reverse transcribed to cDNA using random hexaprimers
and SuperScript III reverse transcriptase (Thermo Fisher Scientific, Inc.). Quantitative PCR
was performed using PowerUP Sybr green master mix (Thermo Fisher Scientific, Inc.)
on the QuantStudio3 system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The
QuantStudio Design and Analysis software v1.5.0 (Applied Biosystems; Thermo Fisher
Scientific, Inc.), was used to calculate mRNA levels with the 2−∆∆Cq method and ß-actin
was used as reference. All experiments were performed in triplicate. Oligonucleotide
primers were purchased from Sigma-Aldrich and the sequences of the primers are available
upon request.
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4.5. Western Blot Analysis
SW1736 and 8505C parental or PTX-resistant cells were untreated or treated with
2.5 µM DHT or DMSO. After 72 h treatment, total proteins were extracted by using a cell
scraper and lysis buffer (50 mM Tris HCl, pH 8; 120 mM NaCl; 5 mM EDTA; 1% Triton;
1% NP40; 1 mM DTT), supplemented with phenyl-methylsulphonyl fluoride and protease
inhibitors. Lysates were centrifuged at 13,000× g for 10 min at 4 ◦C, and supernatants were
quantified using a Bradford assay. For nuclear and cytoplasmic protein extraction, SW1736
and 8505C parental or PTX-resistant cells were lysed by using two buffer with different
ionic force: B1 (HEPES pH 7.9 10 mM, KCl 10 mM, MgCl2 0.1 mM, EDTA pH 8 0.1 mM)
for cytoplasmic proteins extraction and B2 (HEPES pH 7.9 20 mM, NaCl 420 mM, MgCl2
1.5 mM, EDTA pH 8 0.1 mM, glicerolo 5%) for nuclear proteins extraction, as previously
described [53].
To evaluate pSTAT3, STAT3, pERK and ERK protein levels, 30 µg of total proteins
were run on 12% SDS PAGE gel, transferred to PVDF membranes (VWR, Milan, Italy),
blocked with TTBS/milk (TBS, 1% Tween 20 and 5% non-fat dry milk) and incubated
overnight with anti-STAT 3 antibody diluted 1:1000 or anti-phospho-STAT 3 antibody
diluted 1:200 (Cell Signaling, Euroclone, Milan, Italy), anti-ERK antibody diluted 1:1000 or
anti-phospho-ERK antibody diluted 1:500 (Santa Cruz Biotechnology, Dallas, TX, USA) and
anti-β-actin antibody diluted 1:10,000 (Merck Serono, Rome, Italy). The membranes were
incubated with horseradish peroxidase-conjugated antibody (Transduction Laboratories,
Lexington, KY, USA) in TTBS/milk. Western blot detection system ECL Plus (Perkin Elmer,
Monza, Italy) was used to visualize the proteins.
To evaluate ABCB1 and NF-kB protein levels, 30 µg protein was loaded per lane on
a 10% SDS gel, resolved using SDS-PAGE, then transferred to nitrocellulose membranes
(GE Healthcare, Chicago, IL, USA). The membranes were blocked at room temperature for
1 h using PBS-milk (PBS; 0.1% Tween-20; 5% non-fat dry milk). The membranes were then
incubated overnight at 4 ◦C with rabbit anti-actin antibody (1:1000; Sigma-Aldrich; Merck
KGaA), rabbit anti-lamin B1 (1:1000; Abcam, Cambridge, UK), mouse monoclonal anti-
ABCB1 (1:1000; ThermoFisher), rabbit monoclonal anti-NF-kB (1:1000; Active Motif). The
following day, the membranes were incubated with peroxidase-conjugated anti-rabbit or
anti-mouse IgG secondary antibody (both 1:4000; cat. nos. A6154 and A9044, respectively;
both Sigma-Aldrich; Merck KGaA) for 2 h at room temperature. A UVITEC Alliance LD
(Uvitec Ltd., Cambridge, UK) Western blot detection system with SuperSignal Technology
reagent (Thermo Fisher Scientific, Inc) and the Alliance 1D Max software (Uvitec Ltd.) was
used to visualize the signals.
4.6. Soft Agar Assay
The clonogenic ability of the SW1736, 8505C, SW1736-PTX and 8505C-PTX cells
was evaluated using a soft agar assay, as previously described [40]. Briefly, after 48 h of
treatment, cells were collected, and 1 × 104 cells were suspended in 4 mL complete medium
containing 0.25% agarose (Sigma-Aldrich), then seeded to the top of a 1% agarose complete
medium layer in 6-cm plates. The colonies were counted by eye in four different fields,
under a Leica DMI-600B inverted microscope (Leica Microsystems Ltd., Wetzlar, Germany).
Data are representative of three independent experiments.
4.7. Statistical Analysis
Data are presented as the mean ± standard deviation. All results were analyzed using
the unpaired Student’s t-test or the Tukey–Kramer multiple comparisons test in GraphPad
Prism version 6 (GraphPad Software, Inc., San Diego, CA, USA). p < 0.05 was considered
to indicate a statistically significant difference.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/ijms22158083/s1.
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